Nicole Burchardi

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 666 citations

Clinical Results, Breast Oncology, Biomarker Analysis +7

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Lars Hanker, Sibylle Loibl, Nicole Burchardi et al. · Annals of Oncology · 2012 · 333 citations

Medicine, Primary Taxane/platinum-based Therapy, Gynecology +8

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sibylle Loibl, Frederik Marmé, Miguel Martín et al. · Journal of Clinical Oncology · 2021 · 310 citations

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke et al. · Annals of Oncology · 2020 · 136 citations

Breast Oncology, Geparola Study, Medicine +7

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Sibylle Loibl, Andreas Schneeweiß, Jens Huober et al. · Journal of Clinical Oncology · 2021 · 118 citations

Geparnuevo Trial, Breast Oncology, Immunology +17